Review

Cancer Immunology, Immunotherapy

, Volume 53, Issue 3, pp 249-255

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

  • Pedro RomeroAffiliated withDivison of Clinical Onco-Immunology, Lausanne branch, University Hospital (CHUV), Ludwig Institute for Cancer Research Email author 
  • , Jean-Charles CerottiniAffiliated withLausanne Branch, Ludwig Institute for Cancer Research
  • , Daniel E. SpeiserAffiliated withDivison of Clinical Onco-Immunology, Lausanne branch, University Hospital (CHUV), Ludwig Institute for Cancer Research

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Numerous phase I and II clinical trials testing the safety and immunogenicity of various peptide vaccine formulations based on CTL-defined tumor antigens in cancer patients have been reported during the last 7 years. While specific T-cell responses can be detected in a variable fraction of immunized patients, an even smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring antitumor T- and B-cell responses and at sustaining a large number of tumor antigen specific and fully functional effector T cells at tumor sites. Recent progress in our ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field.

Keywords

Cancer vaccines Tumor immunology Immune monitoring Tetramers